Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 11, 2017 - Issue
Submit an article Journal homepage
85
Views
8
CrossRef citations to date
0
Altmetric
Review

Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations

Bernardo Leon Rapoport1 The Medical Oncology Centre of Rosebank, Johannesburg, South AfricaCorrespondence[email protected]
,
Matti Aapro2 Breast Center, Genolier Cancer Center, Genolier, Switzerland
,
Martin R Chasen3 Palliative Care, William Osler Health Services, Brampton, ON, Canada
,
Karin Jordan4 Department of Medicine V, University of Heidelberg, Heidelberg, Germany
,
Rudolph M Navari5 Division of Hematology Oncology, University of Alabama School of Medicine, Birmingham, AL, USA
,
Ian Schnadig6 Compass Oncology, US Oncology Research, Tualatin, OR, USA
&
Lee Schwartzberg7 West Clinic, Memphis, TN, USA
 show all
Pages 2621-2629 | Published online: 05 Sep 2017

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Vito Lorusso, Anna Russo, Francesco Giotta & Paolo Codega. (2020) Management of Chemotherapy-Induced Nausea and Vomiting (CINV): A Short Review on the Role of Netupitant-Palonosetron (NEPA). Core Evidence 15, pages 21-29.
Read now

Articles from other publishers (7)

Joseph S Bubalo, Jennifer L Radke, Kenneth G Bensch, Andy I Chen, Shikha Misra & Richard T Maziarz. (2023) A phase II trial of netupitant/palonosetron for prevention of chemotherapy-induced nausea/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation. Journal of Oncology Pharmacy Practice, pages 107815522311738.
Crossref
Mohamed Fawzi Kabil, Mohamed Y. Mahmoud, Alaa F. Bakr, Dalia Zaafar & Ibrahim M. El-Sherbiny. (2022) Switching indication of PEGylated lipid nanocapsules-loaded with rolapitant and deferasirox against breast cancer: Enhanced in-vitro and in-vivo cytotoxicity. Life Sciences 305, pages 120731.
Crossref
Fatemeh Vazirian, Sara Samadi, Hossein Rahimi, Masoomeh Sadeghi & Amir Hooshang Mohammadpour. (2022) Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review. Cancer Chemotherapy and Pharmacology 90:1, pages 1-6.
Crossref
Cindy Weinstein, Karin Jordan, Stuart Green, Saleem Khanani, Elizabeth Beckford-Brathwaite, Waldimir Vallejos, Annpey Pong, Stephen J. Noga & Bernardo L. Rapoport. (2020) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type. BMC Cancer 20:1.
Crossref
Safieh Ebrahimi, Hosein Javid, Amin Alaei & Seyed Isaac Hashemy. (2020) New insight into the role of substance P/neurokinin‐1 receptor system in breast cancer progression and its crosstalk with microRNAs . Clinical Genetics 98:4, pages 322-330.
Crossref
Janet S. Carpenter. (2020) The protagonist is a neurokinin 1, 3 antagonist. Menopause 27:5, pages 495.
Crossref
Xiaodong Wang, Zhi-Yi Zhang, Jing Wang & Vikram Kansra. (2019) A Phase 1 Assessment of the QT Interval in Healthy Adults Following Exposure to Rolapitant, a Cancer Supportive Care Antiemetic. Clinical Pharmacology in Drug Development 8:5, pages 603-611.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.